Clinical Trials Logo

Clinical Trial Summary

This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life, using validated activities of daily living and questionnaires.


Clinical Trial Description

This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life. In addition, the study will provide additional information about the safety and efficacy of the CE-certified RETINA IMPLANT Alpha AMS. In several studies it has been shown that patients who received this subretinal implant regain visual function to a certain extent and that its use is safe. So far, all assessments of patients with the RETINA IMPLANT Alpha AMS have been done in a controlled environment within the scope of interventional studies where the benefit in daily life has been assessed anecdotally only. Currently, there is no standard method available for an objective assessment of the impact of such devices in daily life of these patients. Hence, the aim of this study is to further assess the impact in daily life with a combination of already validated and newly developed assessments and questionnaires.

This study adheres to the tenets of the Declaration of Helsinki. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03561922
Study type Interventional
Source Retina Implant AG
Contact
Status Terminated
Phase N/A
Start date September 4, 2018
Completion date April 5, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Active, not recruiting NCT03872479 - Single Ascending Dose Study in Participants With LCA10 Phase 1/Phase 2
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Active, not recruiting NCT01736293 - Natural History of Eye Diseases Related to ABCA4 Mutations
Completed NCT03318549 - BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases N/A
Completed NCT04919473 - Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Completed NCT01497379 - Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients N/A
Recruiting NCT04620876 - Bimodal and Coaxial High Resolution Ophtalmic Imaging N/A
Recruiting NCT03592017 - Performance of Long-wavelength Autofluorescence Imaging N/A
Completed NCT03150654 - The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes N/A
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Completed NCT00403195 - Clinical and Pathophysiological Description of Ocular Ischemic Syndrome N/A
Enrolling by invitation NCT06167642 - Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Enrolling by invitation NCT02144103 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Phase 1/Phase 2
Recruiting NCT06289452 - Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis Early Phase 1
Recruiting NCT06305416 - A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Phase 3
Recruiting NCT02617966 - Rod and Cone Mediated Function in Retinal Disease
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3